rss
Br J Ophthalmol 2004;88:925-928 doi:10.1136/bjo.2003.018457
  • Clinical science
    • Extended reports

Transporter associated protein expression in uveal melanoma

  1. S Krishnakumar1,
  2. S A Lakshmi1,
  3. D Abhyankar2,
  4. J Biswas1
  1. 1Department of Ocular Pathology, Vision Research Foundation, Sankara Nethralaya, Chennai, India
  2. 2Evanston North Western Health Care, Evanston, IL, USA
  1. Correspondence to: Dr S Krishnakumar Vision Research Foundation, Sankara Nethralaya, 18 College Road, Chennai-600 006, Tamil Nadu, India; drkrishnakumar_2000yahoo.com
  • Accepted 3 June 2003

Abstract

Background/aim: Transporter associated protein (TAP) is important for presenting peptides to major histocompatibility complex (MHC) class I molecules. Defects in TAP lead to decreased MHC class I expression. The immunoexpression of human leucocyte antigen (HLA) class I molecules and the TAP1 subunit were studied in primary uveal melanomas and correlated with the cell types and extrascleral extension.

Methods: The HLA class I antigen and TAP1 subunit were analysed by immunoperoxidase staining with monoclonal antibodies on 45 primary uveal melanoma archival specimens. The tumours were divided into two groups—group A: tumours with no extrascleral extension; group B tumours with extrascleral extension/liver metastasis. Immunoanalysis was done by a semiquantitative method.

Results: HLA class I antigen and TAP1 were decreased in 35 of 35 tumours with no extrascleral extension and positive in six of 10 tumours with liver metastasis. Decreased immunoexpression of HLA class I antigen and TAP1 in uveal melanomas with no extrascleral extension was significant (p<0.001). HLA class I antigen and TAP1 were negative in spindle cell melanomas (p<0.001).

Conclusions: HLA class I antigen and TAP1 expression were decreased in uveal melanomas with no extrascleral extension and in spindle cell melanomas. Decreased expression of TAP1 may lead to decreased expression of HLA class I antigen in uveal melanomas. This preliminary observation deserves further investigation, which may shed more light on the immune escape mechanisms of this tumour and thus enable novel therapeutic strategies.

Footnotes

  • Commercial relationships: Nil.

This Article

  1. Abstract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Social bookmarking

Register for free content


Free sample
 This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
View free sample issue >>

Free archive
The full back archive is now available for BJO. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.